← back to search

Christopher J. O’Callaghan

Queen's University · CA
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Internal medicine, Temozolomide, Hazard ratio, Radiation therapy, and Colorectal cancer.
h-index
citations
2,250
works
9
NIH funding
primary concept
email

Recent publications

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
New England Journal of Medicine 2025cited by 213position: middledoi
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
BMC Cancer 2023cited by 28position: middledoi
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients
Journal of Neuro-Oncology 2020cited by 23position: middledoi
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.
Journal of Clinical Oncology 2020cited by 0position: middledoi
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
˜The œLancet. Gastroenterology & hepatology 2018cited by 166position: lastdoi
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
New England Journal of Medicine 2017cited by 1,162position: middledoi
Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial
Cancer Epidemiology Biomarkers & Prevention 2016cited by 112position: middledoi
A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).
Journal of Clinical Oncology 2016cited by 53position: middledoi
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
New England Journal of Medicine 2012cited by 493position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Keyue Ding · Queen's University4 papers (2012–2020)Warren Mason · University Health Network3 papers (2016–2020)Chad Winch · Queen's University3 papers (2016–2020)Ryo Nishikawa · Nagoya Institute of Technology3 papers (2016–2020)Johan Menten · KU Leuven3 papers (2016–2020) · 3 papers (2016–2020)Claire Phillips · The University of Melbourne3 papers (2016–2020)Dongsheng Tu · Queen's University3 papers (2016–2025)Derek J. Jonker · Sunnybrook Health Science Centre3 papers (2016–2025)Normand Laperrière · University Health Network3 papers (2016–2020)Sharlene Gill · BC Cancer Agency3 papers (2016–2025)Wolfgang Wick · Heidelberger Institut für Radioonkologie3 papers (2016–2020)Alba A. Brandes · AstraZeneca (Italy)3 papers (2016–2020)James Perry · University of Arkansas for Medical Sciences3 papers (2016–2020)Michael Fay · University of Queensland3 papers (2016–2020)David Osoba · University of Lagos2 papers (2016–2020)Christine M. Friedenreich · University of Calgary2 papers (2016–2025)John Zalcberg · Monash Health2 papers (2018–2023)Matthew Burge · Harbin Medical University2 papers (2016–2025)Janette L. Vardy · University of Sydney2 papers (2016–2025)